These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 34925661)

  • 1. Anagliptin Monotherapy for Six Months in Patients With Type 2 Diabetes Mellitus and Hyper-Low-Density Lipoprotein Cholesterolemia Reduces Plasma Levels of Fasting Low-Density Lipoprotein Cholesterol and Lathosterol: A Single-Arm Intervention Trial.
    Ikegami Y; Takenaka Y; Saito D; Shimada A; Inoue I
    J Clin Med Res; 2021 Nov; 13(10-11):502-509. PubMed ID: 34925661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anagliptin decreases serum lathosterol level in patients with type 2 diabetes: a pilot study.
    Aoki K; Ijima T; Kamiyama H; Kamiko K; Terauchi Y
    Expert Opin Pharmacother; 2015; 16(12):1749-54. PubMed ID: 26098722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differences in lipid metabolism between anagliptin and sitagliptin in patients with type 2 diabetes on statin therapy: a secondary analysis of the REASON trial.
    Chihara A; Tanaka A; Morimoto T; Sakuma M; Shimabukuro M; Nomiyama T; Arasaki O; Ueda S; Node K
    Cardiovasc Diabetol; 2019 Nov; 18(1):158. PubMed ID: 31733647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanism of lipid-lowering action of the dipeptidyl peptidase-4 inhibitor, anagliptin, in low-density lipoprotein receptor-deficient mice.
    Yano W; Inoue N; Ito S; Itou T; Yasumura M; Yoshinaka Y; Hagita S; Goto M; Nakagawa T; Inoue K; Tanabe S; Kaku K
    J Diabetes Investig; 2017 Mar; 8(2):155-160. PubMed ID: 27860391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dipeptidyl peptidase-4 inhibitor anagliptin reduces fasting apolipoprotein B-48 levels in patients with type 2 diabetes: A randomized controlled trial.
    Onoue T; Goto M; Wada E; Furukawa M; Okuji T; Okada N; Kobayashi T; Iwama S; Sugiyama M; Tsunekawa T; Takagi H; Hagiwara D; Ito Y; Morishita Y; Seino Y; Suga H; Banno R; Hamada Y; Ando M; Yamamori E; Arima H
    PLoS One; 2020; 15(1):e0228004. PubMed ID: 31990936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Anagliptin on Glycemic and Lipid Profile in Patients With Type 2 Diabetes Mellitus.
    Chiba Y; Yamakawa T; Tsuchiya H; Oba M; Suzuki D; Danno H; Takatsuka Y; Shigematsu H; Kaneshiro M; Terauchi Y
    J Clin Med Res; 2018 Aug; 10(8):648-656. PubMed ID: 29977423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Lipid-Lowering Effects of Anagliptin and Miglitol in Patients With Type 2 Diabetes: A Randomized Trial.
    Iijima T; Aoki K; Kondo Y; Terauchi Y
    J Clin Med Res; 2020 Feb; 12(2):73-78. PubMed ID: 32095176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dipeptidyl peptidase 4 inhibitor anagliptin ameliorates hypercholesterolemia in hypercholesterolemic mice through inhibition of intestinal cholesterol transport.
    Goto M; Furuta S; Yamashita S; Hashimoto H; Yano W; Inoue N; Kato N; Kaku K
    J Diabetes Investig; 2018 Nov; 9(6):1261-1269. PubMed ID: 29754453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anagliptin, a dipeptidyl peptidase-4 inhibitor, decreases macrophage infiltration and suppresses atherosclerosis in aortic and coronary arteries in cholesterol-fed rabbits.
    Hirano T; Yamashita S; Takahashi M; Hashimoto H; Mori Y; Goto M
    Metabolism; 2016 Jun; 65(6):893-903. PubMed ID: 27173468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Empagliflozin increases plasma levels of campesterol, a marker of cholesterol absorption, in patients with type 2 diabetes: Association with a slight increase in high-density lipoprotein cholesterol.
    Jojima T; Sakurai S; Wakamatsu S; Iijima T; Saito M; Tomaru T; Kogai T; Usui I; Aso Y
    Int J Cardiol; 2021 May; 331():243-248. PubMed ID: 33556413
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dissimilar Effects of Anagliptin and Sitagliptin on Lipoprotein Subclass in Standard or Strong Statin-Treated Patients with Type-2 Diabetes Mellitus: A Subanalysis of the REASON (Randomized Evaluation of Anagliptin versus Sitagliptin on Low-Density LipoproteiN Cholesterol in Diabetes) Trial.
    Hirai H; Higa M; Morimoto T; Sakuma M; Arasaki O; Nomiyama T; Node K; Ueda S; Shimabukuro M
    J Clin Med; 2019 Dec; 9(1):. PubMed ID: 31905896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of anagliptin, a dipeptidyl peptidase-4 inhibitor, in managing type 2 diabetes: A systematic review and meta-analysis.
    Kamrul-Hasan ABM; Dutta D; Nagendra L; Sharma M; Patra S; Bhattacharya S
    Medicine (Baltimore); 2024 Jul; 103(28):e38870. PubMed ID: 38996148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of anagliptin on plasma glucagon levels and gastric emptying in patients with type 2 diabetes: An exploratory randomized controlled trial versus metformin.
    Nakagawa T; Nagai Y; Yamamoto Y; Miyachi A; Hamajima H; Mieno E; Takahashi M; Inoue E; Tanaka Y
    Diabetes Res Clin Pract; 2019 Dec; 158():107892. PubMed ID: 31669625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Ezetimibe Monotherapy on Low-Density Lipoprotein Cholesterol and on Markers of Cholesterol Synthesis and Absorption in Japanese Patients With Hypercholesterolemia.
    Ohta A; Kato H; Ishii S; Nagai Y; Tanaka Y
    J Clin Med Res; 2017 Jun; 9(6):476-481. PubMed ID: 28496547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anagliptin ameliorates albuminuria and urinary liver-type fatty acid-binding protein excretion in patients with type 2 diabetes with nephropathy in a glucose-lowering-independent manner.
    Kitada M; Tsuda SI; Konishi K; Takeda-Watanabe A; Fujii M; Kanasaki K; Nishizawa M; Nakagawa A; Koya D
    BMJ Open Diabetes Res Care; 2017; 5(1):e000391. PubMed ID: 28761658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of anagliptin as compared to linagliptin on metabolic parameters over 2 years of drug consumption: A retrospective cohort study.
    Hamasaki H; Hamasaki Y
    World J Diabetes; 2018 Oct; 9(10):165-171. PubMed ID: 30364744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dipeptidyl peptidase-4 inhibitor anagliptin ameliorates diabetes in mice with haploinsufficiency of glucokinase on a high-fat diet.
    Nakaya K; Kubota N; Takamoto I; Kubota T; Katsuyama H; Sato H; Tokuyama K; Hashimoto S; Goto M; Jomori T; Ueki K; Kadowaki T
    Metabolism; 2013 Jul; 62(7):939-51. PubMed ID: 23790528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anagliptin in the treatment of type 2 diabetes: safety, efficacy, and patient acceptability.
    Nishio S; Abe M; Ito H
    Diabetes Metab Syndr Obes; 2015; 8():163-71. PubMed ID: 25834461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contribution of intestinal dipeptidyl peptidase-4 inhibition for incretin-dependent improved glucose tolerance in mice.
    Yamashita S; Kawakami Y; Sato H; Sugitani S; Goto M; Kato N
    Eur J Pharmacol; 2019 Sep; 859():172521. PubMed ID: 31276666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin.
    Hayashi T; Fukui T; Nakanishi N; Yamamoto S; Tomoyasu M; Osamura A; Ohara M; Yamamoto T; Ito Y; Hirano T
    Cardiovasc Diabetol; 2017 Jan; 16(1):8. PubMed ID: 28086872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.